AVR anteris technologies global corp.

Competitor FDA approval, page-6

  1. 2,518 Posts.
    lightbulb Created with Sketch. 403
    Hi, Nov 2022: Post-procedural outcomes…. report; No moderate or severe paravalvular leak.

    This versus the Abbot device; ‘… to reduce or eliminate paravalvular leak. This seems to be a little too vague, imo.

    Perhaps as somebody has suggested ‘one’ person could contact the company to clarify if there are actual figures to compare the two and then share.

    Would seem to suggest (the FDA app) that this puts Abbot out of the running for interest in Anteris.




 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.56
Change
0.060(1.09%)
Mkt cap ! $86.06M
Open High Low Value Volume
$5.29 $5.70 $5.29 $155.5K 27.95K

Buyers (Bids)

No. Vol. Price($)
2 500 $5.60
 

Sellers (Offers)

Price($) Vol. No.
$5.75 30 1
View Market Depth
Last trade - 15.32pm 07/08/2025 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.